EASL (European Association for the Study of the Liver)

10-14 April, 2019
Vienna, Austria

ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.

Read more »

China Healthcare Investment Conference

26-28 March, 2019

ENYO Pharma has attended the China Healthcare Investment Conference from the 26th to the 28th of March, 2019. It was a great opportunity to initiate several financing and partneurship discussions.

Read more »

J.P. Morgan 37th Annual Healthcare Conference

7 – 10 January, 2019

San Francisco, USA

“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.” (

Read more »

Immunotherapies for Infectious Diseases Congress

10 – 11 December, 2018

Lyon, France

ENYO Pharma’s CSO Eric Meldrum is participating today at the I4ID Congress (Immunotherapies for Infectious Diseases Congress) in Lyon, France. I4ID Congress is dedicated to Host-Directed Therapies to fight infectious diseases. During this event, Eric will present new data from ENYO Pharma preclinical programmes to exemplify the power of ENYO Pharma’s drug discovery approach.

“The 2nd edition I4ID2018, follows the success of the first edition,

Read more »

BioFIT 2018

4 – 5 December, 2018

Lille, France

ENYO Pharma’s CEO Jacky Vonderscher has been invited to speak in the conference programme of BioFIT 2018 in Lille, France, on December 4th and 5th. He had the opportunity to share his experience and knowledge during the following session – agnostic or pure players in the biotech sector: who is becoming prominent in the early-stage financing rounds? He was also able to give ENYO’s experience feedback following the first fundraising in 2016.

Read more »